semaglutide nejm weight loss For patients with #obesity, semaglutide, a glucagon-like peptide-1 receptor agonist, is approved for management as a once-weekly subcutaneous injection. In a previous trial, oral at a dose of 50 mg A Placebo-Controlled Trial of Subcutaneous

The mean follow-up was 4.81.1 years for the GLP-1RAs group and 4.41.4 years for the metformin group

The perspectives below explore how this study looks through several evidence-based lenses.Lens OverviewThe study becomes most useful when its positive, negative, and uncertain findings remain together

The most commonly reported GLP-1 side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, and indigestion

Higher doses may produce longer-lasting appetite control, but they also require careful monitoring

RJS has served on scientific advisory boards for Ethicon Endo-Surgery, Daiichi Sankyo, Janssen, Novartis, Nestle, Takeda, Boehringer Ingelheim, Sanofi and Novo Nordisk and is a paid speaker for Ethicon Endo-Surgery

Nausea and vomiting can also occur